BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

June 18, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search